DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
10647
MGTA-456
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
MGTA-456
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
UDONITRECTAG
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
UDONITRECTAG
×
Maximum Phase:
2
First Approval:
None
UNII:
2GOW9TT6AD
Molecule Type:
Small molecule
Molecular Formula:
C20H19NO5
Molecular Weight:
353.37
AlogP:
1.83
PSA:
76.07
HBD:
1.0
HBA:
#RotB:
5.0
Source:
MILVEXIAN
2
Small molecule
Investigational
Unknown
Unknown
Thrombosis
Unknown
MILVEXIAN
×
Maximum Phase:
2
First Approval:
None
UNII:
0W79NDQ608
Molecule Type:
Small molecule
Molecular Formula:
C28H23Cl2F2N9O2
Molecular Weight:
626.46
AlogP:
5.8
PSA:
125.41
HBD:
1.0
HBA:
#RotB:
4.0
Source:
FORODESINE
2
Small molecule
Investigational
Unknown
Unknown
Leukemia, Biphenotypic, Acute; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, T-Cell, Cutaneous
Unknown
FORODESINE
×
Maximum Phase:
2
First Approval:
None
UNII:
426X066ELK
Molecule Type:
Small molecule
Molecular Formula:
C11H14N4O4
Molecular Weight:
266.26
AlogP:
-2.02
PSA:
134.26
HBD:
6.0
HBA:
#RotB:
2.0
Source:
AT-9283
2
Small molecule
Investigational
Unknown
Unknown
Leukemia; Lymphoma, Non-Hodgkin; Neoplasms; Multiple Myeloma
Serine/threonine-protein kinase Aurora-A inhibitor
AT-9283
×
Maximum Phase:
2
First Approval:
None
UNII:
XAV9KYN9WL
Molecule Type:
Small molecule
Molecular Formula:
C19H23N7O2
Molecular Weight:
381.44
AlogP:
2.07
PSA:
110.96
HBD:
4.0
HBA:
#RotB:
5.0
Source:
ETHYL ISOTHIOCYANATE
2
Small molecule
Investigational
Unknown
Unknown
Lung Neoplasms
Unknown
ETHYL ISOTHIOCYANATE
×
Maximum Phase:
2
First Approval:
None
UNII:
3284MJ2T8P
Molecule Type:
Small molecule
Molecular Formula:
C3H5NS
Molecular Weight:
87.15
AlogP:
1.11
PSA:
12.36
HBD:
0.0
HBA:
#RotB:
1.0
Source:
ENECADIN
2
Small molecule
Investigational
Unknown
Unknown
Stroke
Unknown
ENECADIN
×
Maximum Phase:
2
First Approval:
None
UNII:
VR034VW8OG
Molecule Type:
Small molecule
Molecular Formula:
C21H28FN3O
Molecular Weight:
357.47
AlogP:
4.63
PSA:
38.25
HBD:
0.0
HBA:
#RotB:
8.0
Source:
DALPICICLIB
2
Small molecule
Investigational
Unknown
Unknown
Esophageal Neoplasms
Unknown
DALPICICLIB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C25H30N6O2
Molecular Weight:
446.56
AlogP:
4.02
PSA:
101.8
HBD:
2.0
HBA:
#RotB:
5.0
Source:
DAIDZEIN
2
Small molecule
Investigational
Unknown
Unknown
Osteoporosis
Unknown
DAIDZEIN
×
Maximum Phase:
2
First Approval:
None
UNII:
6287WC5J2L
Molecule Type:
Small molecule
Molecular Formula:
C15H10O4
Molecular Weight:
254.24
AlogP:
2.87
PSA:
70.67
HBD:
2.0
HBA:
#RotB:
1.0
Source:
IMISOPASEM MANGANESE
2
Small molecule
Investigational
Unknown
Unknown
Hypotension
SOD mimic (antioxidant)
IMISOPASEM MANGANESE
×
Maximum Phase:
2
First Approval:
None
UNII:
2Q6R3259KS
Molecule Type:
Small molecule
Molecular Formula:
C21H35Cl2MnN5
Molecular Weight:
483.39
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
CETILISTAT
2
Small molecule
Investigational
Unknown
Unknown
Obesity
Gastric lipase inhibitor
CETILISTAT
×
Maximum Phase:
2
First Approval:
None
UNII:
LC5G1JUA39
Molecule Type:
Small molecule
Molecular Formula:
C25H39NO3
Molecular Weight:
401.59
AlogP:
7.36
PSA:
52.33
HBD:
0.0
HBA:
#RotB:
16.0
Source:
DIHYDREXIDINE
2
Small molecule
Investigational
Unknown
Unknown
Cocaine-Related Disorders
Unknown
DIHYDREXIDINE
×
Maximum Phase:
2
First Approval:
None
UNII:
Q3PJ4B4D0X
Molecule Type:
Small molecule
Molecular Formula:
C17H17NO2
Molecular Weight:
267.33
AlogP:
2.65
PSA:
52.49
HBD:
3.0
HBA:
#RotB:
0.0
Source:
FORALUMAB
2
Antibody
Investigational
Unknown
Unknown
Crohn Disease; Graft vs Host Disease
T cell surface glycoprotein CD3 inhibitor
FORALUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
J43DL56H6M
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TMC-647055
2
Small molecule
Investigational
Unknown
Unknown
Hepatitis C; Hepatitis C, Chronic
Hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitor
TMC-647055
×
Maximum Phase:
2
First Approval:
None
UNII:
11BD024G7J
Molecule Type:
Small molecule
Molecular Formula:
C32H38N4O6S
Molecular Weight:
606.75
AlogP:
4.16
PSA:
110.18
HBD:
1.0
HBA:
#RotB:
2.0
Source:
OZANEZUMAB
2
Antibody
Investigational
Unknown
Unknown
Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Amyotrophic Lateral Sclerosis
Reticulon-4 inhibitor
OZANEZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
123I05210W
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DRF-10945
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Peroxisome proliferator-activated receptor alpha agonist
DRF-10945
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
XEN-D0501
2
Small molecule
Investigational
Unknown
Unknown
Cough; Diabetes Mellitus, Type 2; Pulmonary Disease, Chronic Obstructive
Vanilloid receptor antagonist
XEN-D0501
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TASIDOTIN
2
Protein
Investigational
Unknown
Unknown
Unknown
Unknown
TASIDOTIN
×
Maximum Phase:
2
First Approval:
None
UNII:
05G07285DK
Molecule Type:
Protein
Molecular Formula:
C32H58N6O5
Molecular Weight:
606.85
AlogP:
2.09
PSA:
122.37
HBD:
2.0
HBA:
#RotB:
11.0
Source:
PG2
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
PG2
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PELACARSEN
2
Oligonucleotide
Investigational
Unknown
Unknown
Kidney Diseases; Cardiovascular Diseases
Unknown
PELACARSEN
×
Maximum Phase:
2
First Approval:
None
UNII:
LSO9H7UZ90
Molecule Type:
Oligonucleotide
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
JNJ-18038683
2
Small molecule
Investigational
Unknown
Unknown
Bipolar Disorder; Depressive Disorder, Major
Serotonin 7 (5-HT7) receptor antagonist
JNJ-18038683
×
Maximum Phase:
2
First Approval:
None
UNII:
28PGH5X4OQ
Molecule Type:
Small molecule
Molecular Formula:
C20H20ClN3
Molecular Weight:
337.85
AlogP:
3.94
PSA:
29.85
HBD:
1.0
HBA:
#RotB:
3.0
Source:
TD-1792
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
TD-1792
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CPI-0610
2
Small molecule
Investigational
Unknown
Unknown
Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Primary Myelofibrosis; Peripheral Nervous System Neoplasms
Bromodomain and extra-terminal motif (BET) inhibitor
CPI-0610
×
Maximum Phase:
2
First Approval:
None
UNII:
U4017GUQ06
Molecule Type:
Small molecule
Molecular Formula:
C20H16ClN3O2
Molecular Weight:
365.82
AlogP:
4.07
PSA:
81.48
HBD:
1.0
HBA:
#RotB:
3.0
Source:
BNC-210
2
Unknown
Investigational
Unknown
Unknown
Psychomotor Agitation; Stress Disorders, Post-Traumatic
Unknown
BNC-210
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BIRICODAR DICITRATE
2
Small molecule
Investigational
Unknown
Unknown
Lung Neoplasms
Unknown
BIRICODAR DICITRATE
×
Maximum Phase:
2
First Approval:
None
UNII:
9WQP0L619L
Molecule Type:
Small molecule
Molecular Formula:
C46H57N3O21
Molecular Weight:
987.96
AlogP:
5.02
PSA:
117.15
HBD:
0.0
HBA:
#RotB:
15.0
Source:
VAROGLUTAMSTAT
2
Small molecule
Investigational
Unknown
Unknown
Alzheimer Disease
Unknown
VAROGLUTAMSTAT
×
Maximum Phase:
2
First Approval:
None
UNII:
E3DSH8LL4L
Molecule Type:
Small molecule
Molecular Formula:
C19H20N4O2
Molecular Weight:
336.4
AlogP:
3.62
PSA:
70.25
HBD:
2.0
HBA:
#RotB:
5.0
Source:
MEM 3454
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
MEM 3454
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
FIACITABINE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
FIACITABINE
×
Maximum Phase:
2
First Approval:
None
UNII:
4058H365ZB
Molecule Type:
Small molecule
Molecular Formula:
C9H11FIN3O4
Molecular Weight:
371.11
AlogP:
-0.98
PSA:
110.6
HBD:
3.0
HBA:
#RotB:
2.0
Source:
MK-4280
2
Unknown
Investigational
Unknown
Unknown
Carcinoma, Renal Cell; Hodgkin Disease; Lymphoma, Non-Hodgkin; Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Non-Small-Cell Lung
Lymphocyte activation gene 3 protein inhibitor
MK-4280
×
Maximum Phase:
2
First Approval:
None
UNII:
H1396W7D1H
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
S-ADENOSYL-L-METHIONINE
2
Small molecule
Investigational
Unknown
Unknown
Hepatitis C; Tobacco Use Disorder
Unknown
S-ADENOSYL-L-METHIONINE
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C15H22N6O5S
Molecular Weight:
398.45
AlogP:
-3.26
PSA:
185.46
HBD:
4.0
HBA:
#RotB:
7.0
Source:
IMALUMAB
2
Antibody
Investigational
Unknown
Unknown
Unknown
Macrophage migration inhibitory factor inhibitor
IMALUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
22F97PC79G
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
VATIQUINONE
2
Small molecule
Investigational
Unknown
Unknown
Muscular Diseases; Tourette Syndrome; Child Development Disorders, Pervasive; Friedreich Ataxia; Hearing Loss, Noise-Induced; Leigh Disease; Mitochondrial Diseases; Parkinson Disease; Rett Syndrome
Quinone reductase 1) modulator
VATIQUINONE
×
Maximum Phase:
2
First Approval:
None
UNII:
6O85FK9I0X
Molecule Type:
Small molecule
Molecular Formula:
C29H44O3
Molecular Weight:
440.67
AlogP:
7.52
PSA:
54.37
HBD:
1.0
HBA:
#RotB:
12.0
Source:
CANTUZUMAB RAVTANSINE
2
Antibody
Investigational
Unknown
Unknown
Colorectal Neoplasms; Pancreatic Neoplasms; Stomach Neoplasms
Mucin-1 binding agent
CANTUZUMAB RAVTANSINE
×
Maximum Phase:
2
First Approval:
None
UNII:
RNQ8JQ4R9P
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
NEFIRACETAM
2
Small molecule
Investigational
Unknown
Unknown
Alzheimer Disease
Unknown
NEFIRACETAM
×
Maximum Phase:
2
First Approval:
None
UNII:
1JK12GX30N
Molecule Type:
Small molecule
Molecular Formula:
C14H18N2O2
Molecular Weight:
246.31
AlogP:
1.86
PSA:
49.41
HBD:
1.0
HBA:
#RotB:
3.0
Source:
RO4998452
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
RO4998452
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
1
2
…
182
183
184
185
186
187
188
…
304
305
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA